about
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variantSimvastatin is associated with a reduced incidence of dementia and Parkinson's diseaseCyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation.Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligandsSimvastatin and dipentyl phthalate lower ex vivo testicular testosterone production and exhibit additive effects on testicular testosterone and gene expression via distinct mechanistic pathways in the fetal rat.Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Sleep apnea and cardiovascular disease.LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesStatins: mechanism of action and effects.New cholesterol guidelines, new treatment challenges.Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.Aggressive lipid management for cardiovascular prevention: evidence from clinical trials.Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromesThe link between cholesterol and Alzheimer's disease.Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia.Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery.Use of lipid-lowering agents (statins) during pregnancy.Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials.MicroRNA-30c Mimic Mitigates Hypercholesterolemia and Atherosclerosis in MiceLovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts.Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1.AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes.K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.PAF-receptor antagonists, lovastatin, and the PTK inhibitor genistein inhibit H2O2 secretion by macrophages cultured on oxidized-LDL matrices.Low-dose statin treatment increases prostate cancer aggressiveness.Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats
P2860
Q24322624-24C26574-2A3D-4B80-9E79-2C9CDC199034Q24673755-8DA20FE0-9DB4-4B8B-AF5F-90A912EB34CEQ33951689-D3F58D1B-DDC2-46E8-A480-979A0D8E8C98Q34075414-E21B79EC-E3AB-4E33-9EA4-2F19BEED8054Q34083979-AC03C39E-5506-4054-BA83-8277659E46F4Q34354290-3AE3E590-544C-40D3-91D8-E82E5E6E908CQ34356147-50E26E86-BAE3-449A-965F-B1D5073CA0EEQ34445660-BDA7CB5E-3426-4629-988B-EA32AF0DA7B6Q34467343-F2160E4F-23E4-4DF1-902C-F664BBBE2CAFQ34467839-0BFC233C-6981-467A-B175-69164916273DQ34687736-10DFFCFF-FF46-4613-9C9D-02FB720AB667Q34748825-5B15FF6A-8486-4B66-A11B-D85051BE9A89Q35009456-DE1FEEA1-C7C8-4D28-BE24-C180A7C31520Q35183108-4F5A0619-D6F2-4B2E-B8BC-17116ABD70D2Q36095925-76F0EAA0-28E0-4A4E-9885-FE142E2CD7E1Q36255194-D032505C-2710-457B-80B2-21D69577B208Q36386569-9570F99D-223E-404F-82DB-229073B3C503Q36402654-EB16BE81-634B-41F2-B250-3CB225F1EAB9Q36406307-A1F0955B-711C-4907-8CFF-ED0B07235020Q38229263-FB26EC46-72A2-465A-8265-9D1E10520529Q40672377-A4547F5E-7808-4581-80D6-3D586272A3CAQ41084475-AC274BCE-7B89-4D58-8BF0-07CB952C346DQ41915318-9FF0E941-0913-49DA-9220-F66311894530Q42206263-955B6F65-3E25-4A8A-AA32-961628A263E6Q43673473-71135950-7DF5-47C0-AF01-9F6DEE75EB6DQ43710351-8201A5A5-93E7-4B0D-B372-36E9B7533412Q43926585-E7A8EEB7-E088-4DCE-B2C9-295BD3F3CB5EQ46160839-FD323F0B-E96D-41AC-B31F-2959417CFE58Q46693946-FD6556BC-2F7A-45C1-8C3F-EDC565996023Q46769773-357254AE-A077-4A87-A8CA-AB68F16036B1Q49823811-49B8475E-31C5-4FF6-8E24-2E12AA6F513BQ57476056-C4300DF7-B2D0-4852-9E71-7E33B8529528
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Statins: effective antiatherosclerotic therapy.
@ast
Statins: effective antiatherosclerotic therapy.
@en
type
label
Statins: effective antiatherosclerotic therapy.
@ast
Statins: effective antiatherosclerotic therapy.
@en
prefLabel
Statins: effective antiatherosclerotic therapy.
@ast
Statins: effective antiatherosclerotic therapy.
@en
P1476
Statins: effective antiatherosclerotic therapy.
@en
P2093
Blumenthal RS
P304
P356
10.1016/S0002-8703(00)90033-4
P407
P577
2000-04-01T00:00:00Z